RxDoctor Payments Data

Rachit Vakil, MD

Cardiovascular Disease · Moorestown, NJNPI 1356705180

Payments from drug & device makers

What this record shows

This record is dominated by grants: $21,500 of the $29,839 with a category attached, or 72.1%. Boston Scientific accounts for 78.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $19,035 and has fallen 96.3% since, to $704 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,839in general payments, 2019–2025

Across 102 payments — averaging $292.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$23K
  • Medtronic$3K
  • Biotronik Inc.$1K
  • Abbott$951
  • Biosense Webster, Inc.$759
  • Cardiva Medical, Inc.$244
  • plus $33 from 2 others

What the payments were for

  • Grants$21,50072%
  • Travel & lodging$3,75913%
  • Food & beverage$4,04714%
  • Education$5322%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,839 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey →

Medicare billing

Part B allowed, 2024
$31,348
Medicare patients
83
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$13,451

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Moorestown

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →